Evaluation of Patient and Physician Reported Reasons for Switching FVIII Replacement Therapies
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2018
Price : $35 *
At a glance
- Drugs Efmoroctocog alfa (Primary) ; Lonoctocog alfa (Primary) ; Octocog alfa (Primary) ; Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms PARkER
- Sponsors Bayer
- 26 Sep 2018 Status changed from recruiting to completed.
- 23 Jul 2018 Planned End Date changed from 30 Jun 2018 to 30 Aug 2018.
- 23 Jul 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Aug 2018.